Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Nope wrong again

<< Previous

Bullboard Posts

Next >>

Comment by Canary001on Apr 08, 2022 2:31pm

171 Views

Post# 34588754

RE:RE:Nope wrong again

You have the meaning of that PR backwards. Bob took an asset that he could not monetize (the GVHD program), that therefore was without value to Claritas, and he returned the asset and was able to get Talent to forgive $4.3 million in liabilities owed to them by Claritas. Bob thereby reduced Claritas' balance sheet liabiltiies by $4.3 million and gave up nothing other than a non-performing asset. Either a) you don't get that, in which case your mind is a non-performing asset, or b) you are a pissed-off Talent shareholder. So which is it?

<< Previous

Bullboard Posts

Next >>

Options trading in a volatile macro environment